Opinion|Videos|January 1, 2025
Current FCS Standard-of-Care Treatment Recommendations
Key Takeaways
- Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
- Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Panelists discuss the current standard-of-care treatment recommendations for familial chylomicronemia syndrome (FCS) from an endocrinologist’s perspective, addressing the use of fibrates, omega-3 fatty acids, and statins despite their lack of approval for FCS; their typical impact on triglyceride reduction; the reasons these therapies are often ineffective in FCS; the gaps in existing treatments; and the associated risks of acute pancreatitis and hospitalization, along with potential adverse effects of these therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- As an endocrinologist, what are your perspectives on current standard-of-care treatment recommendations for FCS, given there are currently no approved treatments for FCS (eg, fibrates, omega-3 fatty acids, statins)?
- What is the typical reduction in triglycerides from using these treatments?
- Why are standard lipid-lowering therapies typically ineffective for patients with FCS?
- What are the gaps in existing treatments for FCS in terms of reducing triglyceride levels, and how do these gaps contribute to the risk of acute pancreatitis and the need for hospitalization?
- What are the potential adverse effects associated with the FCS therapies we just reviewed?
Advertisement
Related to this article
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.
Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.
Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.
Topline data show a 69% placebo-adjusted drop in serum bile acids, with an sNDA planned for the first half of 2027.
Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD
3
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
4
ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
5